藥明康德(02359.HK):3億美元可轉債轉換價調整為每股H股66.17港元
格隆匯6月7日丨藥明康德(02359.HK)公吿,3億美元於2024年到期零息可轉換債券轉換價進一步調整。根據債券的條款與條件,於轉換時所發行H股的價格("轉換價")會由於(其中包括)本公司資本分配及資本公積轉增股本而調整。因此公司宣佈,由於股東於2020年度股東周年大會批准2020年利潤分配及2020年資本公積轉增股本(自2021年6月8日(即緊隨確定H股股東獲得2020年資本公積轉增股本及2020年利潤分配資格的記錄日期後日)生效),以及2020年間對債券轉換價作出的若干輕微約整(毋須即時反映,並已根據債券的條款及條件結轉),債券轉換價會由每股H股79.85港元進一步調整為每股H股66.17港元("經進一步調整轉換價")。除上述者外,債券所有其他條款維持不變。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.